Immuneering Corp (IMRX) News

Immuneering Corp (IMRX): $5.00

-0.41 (-7.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter IMRX News Items

IMRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMRX News Highlights

  • IMRX's 30 day story count now stands at 5.
  • Over the past 24 days, the trend for IMRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about IMRX are DRUG and ESP.

Latest IMRX News From Around the Web

Below are the latest news stories about Immuneering Corp that investors may wish to consider to help them evaluate IMRX as an investment opportunity.

Immuneering Announces Participation in March Investor Conferences

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cellsCAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that management will participate in two March

Yahoo | February 24, 2022

Immuneering Corp (IMRX) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 11, 2022

Should You Buy Immuneering (IMRX) Ahead of Earnings?

Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 7, 2022

What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)?

The big shareholder groups in Immuneering Corporation ( NASDAQ:IMRX ) have power over the company. Large companies...

Yahoo | January 31, 2022

Immuneering Announces Participation in Upcoming Investor Conferences

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cellsCAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Ben Zeskind, Ph.D., Co-Founder, Presiden

Yahoo | January 24, 2022

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board memberBOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company’s Board of Directors. “We are very pleased that Laurie has agreed to join as Chair of our Board of Directors – she is a seasoned executive and Board member who has been a key member of

Yahoo | January 19, 2022

Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.

Industry Executive Brings More than 20 Years of Clinical Drug Development ExpertiseCAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines C

Yahoo | January 18, 2022

Wall Street Analysts Are Bullish on Top Services Picks

There's a lot to be optimistic about in the Services sector as 2 analysts just weighed in on Scientific Games (SGMS – Research Report) and Immuneering (IMRX – Research Report) with bullish sentiments. Scientific Games (SGMS) In a report released yesterday, David Katz from Jefferies maintained a Buy rating on Scientific Games, with a price target of $96.00. The company's shares closed last Thursday at $62.63. According to TipRanks.

Howard Kim on TipRanks | January 7, 2022

Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event

Preclinical Data Suggest IMM-1-104 May Offer Unique Therapeutic Advantage Compared with Binimetinib in NRAS Mutant Tumors Data to be discussed in Key External Expert event on January 6 2022, 5PM Eastern Time CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced preclinical d

Yahoo | January 6, 2022

Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately. In this role, Dr. Steinhertz will focus on working with Immuneering'

Yahoo | January 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4748 seconds.